CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,995 enrolled
Drug / intervention
Peginterferon alfa-2b (SCH 54031) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00727259
NCT00727259N/ACompleted
CompareCT.gov

Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C

Merck Sharp & Dohme LLC·observational·Posted Aug 1, 2008·Updated Apr 29, 2015

In Brief

An observational study evaluating Peginterferon alfa-2b (SCH 54031) and Ribavirin (SCH 18908) for Hepatitis C, Chronic. Completed, enrolled 1,995 participants.

Detailed Summary

The current gold standard for treatment of chronic hepatitis C (CHC) patients is with pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will definitely determine treatment effectiveness. This is the idea behind the development and usage of the PegPen. The goal of this study is to determine the satisfaction grade with this novel device.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 1, 2008
Enrollment StartOct 1, 2004
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 17.9 years ago

Interventions

Peginterferon alfa-2b (SCH 54031)biological

Peginterferon alfa-2b will be administered according to the products' labeling.

Ribavirin (SCH 18908)drug

Ribavirin will be administered according to the products' labeling.